City
Epaper

India's Covid-19 vaccines will benefit most countries, says Bhutan Ambassador

By ANI | Updated: December 10, 2020 01:10 IST

Bhutan's Ambassador to India on Wednesday said that the Covid-19 vaccines in India will benefit most countries, as they would be the easiest to administer and transport.

Open in App

Bhutan's Ambassador to India on Wednesday said that the Covid-19 vaccines in India will benefit most countries, as they would be the easiest to administer and transport.

Speaking to foreign envoys onboard a plane to New Delhi, Ambassador Vetsop Namgyel said: "Vaccines in India are the ones which will be easiest to administer and transport. Most countries will benefit from it. India is known to produce in bulk quantities, once approved it can be rolled out quickly."

Namgyel was among the 60 foreign heads of missions who visited the facilities of two pharmaceutical firms working on Covid-19 vaccines- the Bharat Biotech and the Biological E.

F Svane, Ambassador of Denmark to India, said that India is not working for commercial or national interest but is also working for countries around the world.

While praising Prime Minister Narendra Modi, Mahima Datla, the Managing Director of the Biological E Ltd, said it is a testament to PM Modi's vision who's not only showcasing collaboration but is keen to ensure that Indian compes play a vital role in delivering vaccines around the world.

Sources had informed that there is a lot of interest in India's vaccine development efforts.

PM Modi has said that India's vaccine production and delivery capacity will be used to help all humty in fighting this crisis.

He visited the Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute of India in Pune on November 28 to conduct an extensive review of the vaccine development and manufacturing process.

Bharat Biotech had on Monday applied for emergency use authorisation for its indigenously developed Covid-19 vaccine 'Covaxin' to Drugs Controller General of India (DCGI).

It is the second Indian company to apply for emergency use authorisation after the Serum Institute of India applied for such use for the vaccine developed by Oxford University and AstraZeneca.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

InternationalUS pursues sanctioned oil tanker near Venezuela after vessel refuses to stop

NationalDense fog in parts of Rajasthan; visibility drops to 10 metres

Cricket"Why doesn't the ICC pay for it?" Mitchell Starc on DRS controversy

BusinessIndia, New Zealand announce free trade agreement; to serve as catalyst for trade, investment

BusinessAnil Ambani’s Reliance Infra Trading Restricted After Upper Circuit, Investors Face Limited Exit

International Realted Stories

InternationalBangladeshi community, journalists in London condemn attacks on media outlets back home

International'Nobel Peace Prize is symbol of justice, not silence': Calls grow for action against Yunus amid B'desh violence

InternationalTrump appoints Louisiana Governor Jeff Landry as special envoy to Greenland

International"Hostility towards India being manufactured by extremists," says ex-Bangladesh PM Sheikh Hasina; blames Yunus-led interim govt

InternationalInnospace plans S. Korea's 1st commercial orbital rocket launch this week